Trial Outcomes & Findings for An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants (NCT NCT05275023)

Last Updated: 2025-04-25

Results Overview

Percentage of participants who achieved HBsAg seroclearance at FU Week 24 were reported. Seroclearance of HBsAg was defined as a (quantitative) HBsAg level less than (\<) lower limit of quantification (LLOQ) (0.05 international unit per milliliters \[IU/mL\]).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

37 participants

Primary outcome timeframe

At FU Week 24

Results posted on

2025-04-25

Participant Flow

Participant milestones

Participant milestones
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + Nucleos(t)Ide Analog (NA) In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 milligrams per kilogram (mg/kg) as intravenous (IV) infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to follow up (FU) Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Intervention Phase: Week 0 to Week 24 STARTED	18	19
Intervention Phase: Week 0 to Week 24 COMPLETED	18	19
Intervention Phase: Week 0 to Week 24 NOT COMPLETED	0	0
FU Phase: FU Week 1 to FU Week 48 STARTED	18	19
FU Phase: FU Week 1 to FU Week 48 COMPLETED	18	19
FU Phase: FU Week 1 to FU Week 48 NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	Total n=37 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	18 Participants n=5 Participants	19 Participants n=7 Participants	37 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	15 Participants n=7 Participants	30 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	5 Participants n=7 Participants	5 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	18 Participants n=5 Participants	14 Participants n=7 Participants	32 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	7 Participants n=5 Participants	7 Participants n=7 Participants	14 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) White	11 Participants n=5 Participants	11 Participants n=7 Participants	22 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Region of Enrollment CANADA	3 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants
Region of Enrollment FRANCE	0 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants
Region of Enrollment ITALY	3 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants
Region of Enrollment SPAIN	2 Participants n=5 Participants	5 Participants n=7 Participants	7 Participants n=5 Participants
Region of Enrollment TAIWAN	3 Participants n=5 Participants	4 Participants n=7 Participants	7 Participants n=5 Participants
Region of Enrollment TURKEY	6 Participants n=5 Participants	3 Participants n=7 Participants	9 Participants n=5 Participants
Region of Enrollment UNITED KINGDOM	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
AgeContinuous	40.7 years STANDARD_DEVIATION 7.75 • n=5 Participants	47.9 years STANDARD_DEVIATION 5.05 • n=7 Participants	44.4 years STANDARD_DEVIATION 7.38 • n=5 Participants

PRIMARY outcome

Timeframe: At FU Week 24

Population: Full analysis set (FAS) included all participants who were randomly assigned to an intervention arm in this intervention-specific appendix (ISA) and received at least 1 dose of study intervention within this ISA.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants Who Achieved Hepatitis B Surface Antigen (HBsAg) Seroclearance at Follow-up (FU) Week 24	0 Percentage of participants	0 Percentage of participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA.

An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily had a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention was considered to be treatment emergent. AEs of interest were significant AEs that are judged to be of special interest because of clinical importance, known class effects or based on nonclinical signals.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) of Special Interest IP	11.1 Percentage of participants	5.3 Percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) of Special Interest FU Phase	0 Percentage of participants	5.3 Percentage of participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA.

Number of participants with TEAEs by severity were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that did not necessarily had a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention was considered to be treatment emergent. Severity of AE were graded by using Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale that ranges from Grade 1 to Grade 5. Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicated a potentially life-threatening event, Grade 5 indicated death.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With TEAEs by Severity IP: Grade 1	5 Participants	7 Participants
Number of Participants With TEAEs by Severity IP: Grade 2	1 Participants	5 Participants
Number of Participants With TEAEs by Severity IP: Grade 3	0 Participants	0 Participants
Number of Participants With TEAEs by Severity IP: Grade 4	0 Participants	0 Participants
Number of Participants With TEAEs by Severity IP: Grade 5	0 Participants	0 Participants
Number of Participants With TEAEs by Severity FU Phase: Grade 1	7 Participants	6 Participants
Number of Participants With TEAEs by Severity FU Phase: Grade 2	1 Participants	2 Participants
Number of Participants With TEAEs by Severity FU Phase: Grade 3	0 Participants	0 Participants
Number of Participants With TEAEs by Severity FU Phase: Grade 4	0 Participants	0 Participants
Number of Participants With TEAEs by Severity FU Phase: Grade 5	0 Participants	0 Participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA.

Number of participants with immune related TEAEs were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that did not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Any AE occurring at or after the initial administration of study intervention was considered to be treatment emergent. Immune-related AEs (irAEs) were alanine aminotransferase/alanine aminotransferase (ALT/AST) elevations including immune-related hepatic AEs, infusion-related reaction (IRRs) and other irAEs (including gastrointestinal AEs, neurological AEs, pulmonary AEs, renal AEs, endocrinopathies, rash, uveitis and visual complaints, lipase/amylase elevations, and infection), hematological abnormalities and injection site reactions.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With Immune Related TEAEs IP	0 Participants	0 Participants
Number of Participants With Immune Related TEAEs FU Phase	0 Participants	1 Participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA.

Number of participants with abnormalities in vital signs measurements (including pulse rate: abnormally low: less than or equal to \[\<=\] 45 beats per minute \[bpm\], abnormally high: greater than or equal to \[\>=\] 120 bpm; diastolic blood pressure \[BP\]: abnormally low: \<=50 millimeters of mercury \[mmHg\], mild: \>90 to \<100 mmHg, moderate: \>=100 to \<110 mmHg, and severe: \>=110 mmHg; systolic BP: abnormally low: \<=90 mmHg, mild: \>140 to \<160 mmHg, moderate: \>=160 to \<180 mmHg, and severe: \>=180 mmHg) were reported.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With Abnormalities in Vital Signs IP: Pulse: Abnormally Low	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs IP: Pulse: Abnormally High	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs IP: Diastolic BP: Abnormally Low	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs IP: Diastolic BP: Mild	0 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs IP: Diastolic BP: Moderate	0 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs IP: Diastolic BP: Severe	0 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs IP: Systolic BP: Abnormally low	2 Participants	2 Participants
Number of Participants With Abnormalities in Vital Signs IP: Systolic BP: Mild	2 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs IP: Systolic BP: Moderate	0 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs IP: Systolic BP: Severe	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Pulse: Abnormally low	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Pulse: Abnormally high	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Diastolic BP: Abnormally low	0 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Diastolic BP: Mild	1 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Diastolic BP: Moderate	0 Participants	1 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Diastolic BP: Severe	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Systolic BP: Abnormally low	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Systolic BP: Mild	2 Participants	2 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Systolic BP: Moderate	0 Participants	0 Participants
Number of Participants With Abnormalities in Vital Signs FU Phase: Systolic BP: Severe	0 Participants	0 Participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA. Here, 'n' (number analyzed) refers to number of participants evaluable at specified parameter.

Number of participants with abnormalities in 12-lead ECGs: heart rate (abnormally low: \<45 beats per minute \[bpm\], abnormally high: greater than or equal \[\>=\] 120 bpm), PR interval (abnormally high: greater than \[\>\] 220 millisecond \[msec\]), QRS interval (abnormally high: \>=120 msec), QTc interval Fridericia (Borderline prolonged QT: 450\< QTc \<=480 msec; Prolonged QT: 480 \< QTc \<=500; Pathologically prolonged QT: QTc \>500) were reported.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: QTc interval: Pathologically prolonged QT	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase: Heart rate: Abnormally low	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase: Heart rate: Abnormally high	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase: PR interval: Abnormally high	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase: QRS interval: Abnormally high	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase: QTc interval Borderline prolonged QT	0 Participants	1 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase: QTc interval: prolonged QT	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) FU Phase:QTc interval: Pathologically prolonged QT	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: Heart rate: Abnormally low	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: Heart rate: Abnormally high	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: PR interval: Abnormally high	1 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: QRS interval: Abnormally high	0 Participants	0 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: QTc interval: Borderline prolonged QT	0 Participants	1 Participants
Number of Participants With Abnormalities in 12-lead Electrocardiogram (ECGs) IP: QTc interval: prolonged QT	0 Participants	0 Participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA.

Number of participants with abnormalities in physical examinations were reported.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With Abnormalities in Physical Examinations IP	0 Participants	2 Participants
Number of Participants With Abnormalities in Physical Examinations FU Phase	2 Participants	1 Participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Percentage of participants with abnormalities in hematology parameters (including basophils/Leukocytes high, erythrocytes mean corpuscular volume high, erythrocytes high and low, lymphocytes/leukocytes high and low, monocytes/leukocytes high and low, neutrophils, segmented+band form high and low, reticulocytes/erythrocytes high and low, basophils/leukocytes, eosinophils/leukocytes high, erythrocyte mean corpuscular hemoglobin low, reticulocytes/erythrocytes high and low, lymphocytes atypical/leukocytes high, lymphocytes atypical high, hematocrit high, monocytes low and high) were reported. Abnormalities with at least 1 participant is included. Low and high categorization depend on investigator's discretion.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Basophils/Leukocytes: High	11.1 Percentage of participants	42.1 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Erythrocytes Mean Corpuscular Volume: High	16.7 Percentage of participants	0 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Erythrocytes: Low	16.7 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Erythrocytes: High	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Lymphocytes/Leukocytes: Low	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Lymphocytes/Leukocytes: High	11.1 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Monocytes/Leukocytes: Low	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Monocytes/Leukocytes: High	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Neutrophils, Segmented+Band Form: Low	22.2 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Neutrophils, Segmented+Band Form: High	11.1 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Reticulocytes/Erythrocytes: Low	0 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology IP: Reticulocytes/Erythrocytes: High	0 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Basophils/Leukocytes: High	11.1 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Eosinophils/Leukocytes: High	0 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Erythrocyte Mean Corpuscular Hemoglobin: Low	5.6 Percentage of participants	0 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Erythrocyte Mean Corpuscular Volume: High	27.8 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Erythrocyte: Low	11.1 Percentage of participants	21.1 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Erythrocyte: High	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Lymphocytes/Leukocytes: Low	11.1 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Lymphocytes/Leukocytes: High	22.2 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Monocytes/Leukocytes: Low	0 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Monocytes/Leukocytes: High	5.6 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Neutrophils, Segmented + Band Form: Low	38.9 Percentage of participants	31.6 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Neutrophils, Segmented + Band Form: High	11.1 Percentage of participants	0 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Reticulocytes/Erythrocytes: Low	16.7 Percentage of participants	42.1 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Reticulocytes/Erythrocytes: High	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Lymphocytes Atypical/Leukocytes: High	—	100 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Lymphocytes Atypical: High	—	100 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Hematocrit: High	5.6 Percentage of participants	0 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Monocytes: Low	5.6 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology FU Phase: Monocytes: High	5.6 Percentage of participants	0 Percentage of participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA. Here, 'n' (number analyzed) signifies number of participants analyzed at each specified timepoint.

Number of participants with abnormalities in clinical chemistry parameters (including C reactive protein high, cystatin C low and high, gamma glutamyl transferase low, high density lipoprotein \[HDL\] cholesterol low and high, indirect bilirubin high, lactate dehydrogenase high, protein high, thyrotropin low and high, free thyroxine high, free triiodothyronine low and high, and urea nitrogen high) were reported. Abnormalities with at least 1 participant is included. Low and high categorization depend on investigator's discretion.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: C Reactive Protein: High	3 Participants	2 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Cystatin C: Low	2 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Cystatin C: High	1 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Gamma Glutamyl Transferase: Low	4 Participants	4 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: HDL Cholesterol: Low	6 Participants	3 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: HDL Cholesterol: High	3 Participants	4 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Indirect Bilirubin: High	1 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Lactate Dehydrogenase: High	2 Participants	2 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Protein: High	1 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Thyrotropin: Low	2 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Thyrotropin: High	1 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Free Thyroxine: High	3 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Triiodothyronine, Free: Low	0 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Triiodothyronine, Free: High	5 Participants	4 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry IP: Urea Nitrogen: High	1 Participants	2 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: C Reactive Protein: High	2 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Chloride: Low	0 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Cystatin C: Low	1 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Cystatin C: High	2 Participants	3 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Gamma Glutamyl Transferase: Low	0 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: HDL Cholesterol: Low	6 Participants	2 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: HDL Cholesterol: High	2 Participants	4 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Indirect Bilirubin: High	1 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Lactate Dehydrogenase: High	2 Participants	2 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Protein: High	1 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Thyrotropin: Low	1 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Thyrotropin: High	1 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Free Thyroxine: Low	1 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Free Thyroxine: High	2 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Free Triiodothyronine: High	6 Participants	3 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Clinical Chemistry FU Phase: Urea Nitrogen: High	1 Participants	1 Participants

SECONDARY outcome

Timeframe: IP: Week 0 up to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: Safety analysis set included all participants who received at least 1 dose of study intervention within this ISA. Here, N (number of participants analyzed) signifies number of participants analyzed for this outcome measure and 'n' (number analyzed) signifies number of participants analyzed at each specified category.

Number of participants with abnormalities in clinical laboratory parameters (including specific gravity high and urine hyaline casts high) were reported. Abnormalities with at least 1 participant is included. Low and high categorization depend on investigator's discretion.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=9 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=11 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Urinalysis IP: Specific Gravity: High	2 Participants	0 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Urinalysis IP: Urine Hyaline Casts: High	1 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Urinalysis FU Phase: Specific Gravity: High	1 Participants	1 Participants
Number of Participants With Abnormalities in Clinical Laboratory Parameters: Urinalysis FU Phase: Urine Hyaline Casts: High	2 Participants	2 Participants

SECONDARY outcome

Timeframe: IP: Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, and End of Study Intervention (EOSI; Week 24); FU Phase: FU Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, and EOS (last visit at FU Week 48)

Population: FAS included all participants who were randomly assigned to an intervention arm in this ISA and received at least 1 dose of study intervention within this ISA. Here, 'n' (number analyzed) signifies number of participants analyzed at each specified timepoints.

Change from baseline in HBsAg levels were reported. International units per milliliters=IU/mL. End of Study Intervention (EOSI) was the last post-baseline visit in study intervention period. End of study (EOS) was the last visit in the study.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Baseline	3.25 log10 IU/mL Standard Deviation 0.472	3.14 log10 IU/mL Standard Deviation 0.542
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 1	-0.19 log10 IU/mL Standard Deviation 0.185	-0.17 log10 IU/mL Standard Deviation 0.135
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 2	-0.26 log10 IU/mL Standard Deviation 0.293	-0.31 log10 IU/mL Standard Deviation 0.330
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 3	-0.34 log10 IU/mL Standard Deviation 0.335	-0.44 log10 IU/mL Standard Deviation 0.405
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 4	-0.40 log10 IU/mL Standard Deviation 0.400	-0.52 log10 IU/mL Standard Deviation 0.525
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 8	-0.80 log10 IU/mL Standard Deviation 0.576	-0.87 log10 IU/mL Standard Deviation 0.695
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 12	-1.32 log10 IU/mL Standard Deviation 0.513	-1.41 log10 IU/mL Standard Deviation 0.687
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 16	-1.77 log10 IU/mL Standard Deviation 0.361	-1.84 log10 IU/mL Standard Deviation 0.548
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: Week 20	-1.97 log10 IU/mL Standard Deviation 0.376	-2.07 log10 IU/mL Standard Deviation 0.549
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels IP: EOSI (Week 24)	-2.01 log10 IU/mL Standard Deviation 0.385	-2.10 log10 IU/mL Standard Deviation 0.563
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 4	-1.93 log10 IU/mL Standard Deviation 0.515	-1.98 log10 IU/mL Standard Deviation 0.590
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 8	-1.99 log10 IU/mL Standard Deviation 0.417	-2.12 log10 IU/mL Standard Deviation 0.613
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 12	-1.93 log10 IU/mL Standard Deviation 0.393	-1.99 log10 IU/mL Standard Deviation 0.574
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 16	-1.85 log10 IU/mL Standard Deviation 0.420	-2.01 log10 IU/mL Standard Deviation 0.648
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 20	-1.77 log10 IU/mL Standard Deviation 0.418	-2.02 log10 IU/mL Standard Deviation 0.584
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 24	-1.70 log10 IU/mL Standard Deviation 0.507	-1.85 log10 IU/mL Standard Deviation 0.616
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 32	-1.64 log10 IU/mL Standard Deviation 0.616	-1.75 log10 IU/mL Standard Deviation 0.606
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 40	-1.38 log10 IU/mL Standard Deviation 0.568	-1.69 log10 IU/mL Standard Deviation 0.904
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: Week 48	-1.23 log10 IU/mL Standard Deviation 0.527	-1.54 log10 IU/mL Standard Deviation 0.929
Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels FU Phase: EOS	-1.26 log10 IU/mL Standard Deviation 0.530	-1.54 log10 IU/mL Standard Deviation 0.929

SECONDARY outcome

Timeframe: IP: Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, and EOSI (Week 24); FU Phase: FU Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, and EOS (last visit at FU Week 48)

Percentage of participants with change in HBsAg levels below/above different cut-offs (\<0.05 IU/mL, \<1 U/mL, \<10 IU/mL, \<100 IU/mL , \<1000 IU/mL) over time were reported. EOSI was the last post-baseline visit in study intervention period. EOS was the last visit in the study.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: EOS: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Baseline: HBsAg < 0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Baseline: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Baseline: HBsAg <10 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Baseline: HBsAg <100 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Baseline: HBsAg <1000 IU/mL	38.9 Percentage of participants	42.1 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 1: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 1: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 1: HBsAg <10 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 1: HBsAg <100 IU/mL	0 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 1: HBsAg <1000 IU/mL	44.4 Percentage of participants	57.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 2: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 2: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 2: HBsAg <10 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 2: HBsAg <100 IU/mL	5.6 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 2: HBsAg <1000 IU/mL	38.9 Percentage of participants	63.2 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 3: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 3: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 3: HBsAg <10 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 3: HBsAg <100 IU/mL	11.1 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 3: HBsAg <1000 IU/mL	50.0 Percentage of participants	63.2 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 4: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 4: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 4: HBsAg <10 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 4: HBsAg <100 IU/mL	11.1 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 4: HBsAg <1000 IU/mL	61.1 Percentage of participants	73.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 8: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 8: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 8: HBsAg <10 IU/mL	0 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 8: HBsAg <100 IU/mL	27.8 Percentage of participants	42.1 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 8: HBsAg <1000 IU/mL	66.7 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 12: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 12: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 12: HBsAg <10 IU/mL	11.1 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 12: HBsAg <100 IU/mL	55.6 Percentage of participants	68.4 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 12: HBsAg <1000 IU/mL	100.0 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 16: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 16: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 16: HBsAg <10 IU/mL	16.7 Percentage of participants	21.1 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 16: HBsAg <100 IU/mL	83.3 Percentage of participants	89.5 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 16: HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 20: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 20: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 20: HBsAg <10 IU/mL	22.2 Percentage of participants	42.1 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 20: HBsAg <100 IU/mL	83.3 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: Week 20: HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: EOSI (Week 24): HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: EOSI (Week 24): HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: EOSI (Week 24): HBsAg <10 IU/mL	33.3 Percentage of participants	52.6 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: EOSI (Week 24): HBsAg <100 IU/mL	88.9 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time IP: EOSI (Week 24): HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBsAg <10 IU/mL	16.7 Percentage of participants	57.1 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBsAg <100 IU/mL	83.3 Percentage of participants	85.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBsAg <1 IU/mL	0 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBsAg <10 IU/mL	33.3 Percentage of participants	52.6 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBsAg <100 IU/mL	88.9 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBsAg <10 IU/mL	29.4 Percentage of participants	50.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBsAg <100 IU/mL	88.2 Percentage of participants	93.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBsAg <10 IU/mL	22.2 Percentage of participants	47.4 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBsAg <100 IU/mL	83.3 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBsAg <1000 IU/mL	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBsAg <10 IU/mL	22.2 Percentage of participants	52.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBsAg <100 IU/mL	83.3 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBsAg <1000 IU/mL	94.4 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBsAg <1 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBsAg <10 IU/mL	16.7 Percentage of participants	42.1 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBsAg <100 IU/mL	72.2 Percentage of participants	84.2 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBsAg <1000 IU/mL	88.9 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBsAg <0.05 IU/mL	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBsAg <1 IU/mL	5.6 Percentage of participants	0 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBsAg <10 IU/mL	16.7 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBsAg <100 IU/mL	72.2 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBsAg <1000 IU/mL	88.9 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBsAg <0.05 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBsAg <10 IU/mL	11.1 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBsAg <100 IU/mL	66.7 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBsAg <1000 IU/mL	88.9 Percentage of participants	89.5 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBsAg <0.05 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBsAg <1 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBsAg <10 IU/mL	11.8 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBsAg <100 IU/mL	64.7 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBsAg <1000 IU/mL	82.4 Percentage of participants	89.5 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: EOS: HBsAg <0.05 IU/mL	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: EOS: HBsAg <10 IU/mL	11.1 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: EOS: HBsAg <100 IU/mL	66.7 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Change in HBsAg Levels Below/Above Different Cut-offs Over Time FU Phase: EOS: HBsAg <1000 IU/mL	83.3 Percentage of participants	89.5 Percentage of participants

SECONDARY outcome

Timeframe: IP: Week 0 to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: FAS included all participants who were randomly assigned to an intervention arm in this ISA and received at least 1 dose of study intervention within this ISA.

Percentage of participants with HBsAg seroclearance were reported. Seroclearance of HBsAg was defined as a HBsAg level \<lower limit of quantification (LLOQ) (0.05 IU/mL).

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With HBsAg Seroclearance IP	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With HBsAg Seroclearance FU Phase	0 Percentage of participants	5.3 Percentage of participants

SECONDARY outcome

Timeframe: IP: Week 0 to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: FAS included all participants who were randomly assigned to an intervention arm in this ISA and received at least 1 dose of study intervention within this ISA. Here, 'N' (number of participants analyzed) signifies number of participants analyzed for this outcome measure and 'n' (number analyzed) signifies number of participants analyzed for specified categories.

Percentage of participants with HBsAg seroconversion were reported. Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance and appearance of anti-HBs antibodies (baseline anti-HBs antibodies \<LLOQ and a post-baseline assessment \>=LLOQ).

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=17 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With HBsAg Seroconversion IP Phase	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With HBsAg Seroconversion FU Phase	0 Percentage of participants	5.6 Percentage of participants

SECONDARY outcome

Timeframe: Week 0 up to FU Week 48 (up to Week 72)

Population: FAS included all participants who were randomly assigned to an intervention arm in this ISA and received at least 1 dose of study intervention within this ISA. N=0 signifies that data could not be collected and analyzed as no participant had event.

Time to achieve HBsAg seroclearance was reported. Seroclearance of HBsAg was defined as a (quantitative) HBsAg level \<LLOQ (0.05 IU/mL).

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=1 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Time to Achieve HBsAg Seroclearance	—	NA Days Interval 450.0 to Here, 'NA' signifies that median and upper limit could not be estimated due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: Week 0 up to FU Week 48 (up to Week 72)

Population: FAS included all participants who were randomly assigned to an intervention arm in this ISA and received at least 1 dose of study intervention within this ISA. Here, N=0 signifies that data could not be collected and analyzed as no participant had event.

Time to achieve HBsAg seroconversion were reported. Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance and appearance of anti-HBs antibodies (baseline anti-HBs antibodies \<LLOQ and a post-baseline assessment \>=LLOQ).

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=1 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Time to Achieve HBsAg Seroconversion	—	NA Days Interval 505.0 to Here, 'NA' signifies that median and upper limit could not be estimated due to insufficient number of participants with events.

SECONDARY outcome

Timeframe: IP: Baseline, Weeks 2, 4, 8, 12, 16, 20 and EOSI (Week 24); FU Phase: FU Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, and EOS (last visit at FU Week 48)

HBV DNA levels over time were reported. EOSI was the last post-baseline visit in study intervention period. EOS was the last visit in the study.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Baseline	0.83 log10 IU/mL Standard Deviation 0.220	0.80 log10 IU/mL Standard Deviation 0.200
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Week 2	0.87 log10 IU/mL Standard Deviation 0.260	0.72 log10 IU/mL Standard Deviation 0.109
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Week 4	0.83 log10 IU/mL Standard Deviation 0.220	0.85 log10 IU/mL Standard Deviation 0.228
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Week 8	0.88 log10 IU/mL Standard Deviation 0.239	0.82 log10 IU/mL Standard Deviation 0.216
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Week 12	0.88 log10 IU/mL Standard Deviation 0.239	0.82 log10 IU/mL Standard Deviation 0.216
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Week 16	0.91 log10 IU/mL Standard Deviation 0.244	0.82 log10 IU/mL Standard Deviation 0.216
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: Week 20	0.86 log10 IU/mL Standard Deviation 0.231	0.80 log10 IU/mL Standard Deviation 0.200
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time IP: EOSI (Week 24)	0.96 log10 IU/mL Standard Deviation 0.281	0.77 log10 IU/mL Standard Deviation 0.179
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 4	0.83 log10 IU/mL Standard Deviation 0.220	0.90 log10 IU/mL Standard Deviation 0.288
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 8	0.83 log10 IU/mL Standard Deviation 0.220	0.80 log10 IU/mL Standard Deviation 0.200
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 12	0.93 log10 IU/mL Standard Deviation 0.257	0.91 log10 IU/mL Standard Deviation 0.244
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 16	0.78 log10 IU/mL Standard Deviation 0.183	0.85 log10 IU/mL Standard Deviation 0.228
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 20	0.86 log10 IU/mL Standard Deviation 0.231	0.90 log10 IU/mL Standard Deviation 0.242
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 24	0.86 log10 IU/mL Standard Deviation 0.231	0.87 log10 IU/mL Standard Deviation 0.236
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 32	0.88 log10 IU/mL Standard Deviation 0.239	0.75 log10 IU/mL Standard Deviation 0.150
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 40	0.91 log10 IU/mL Standard Deviation 0.244	0.85 log10 IU/mL Standard Deviation 0.228
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: Week 48	0.84 log10 IU/mL Standard Deviation 0.224	0.82 log10 IU/mL Standard Deviation 0.216
Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels Over Time FU Phase: EOS	0.83 log10 IU/mL Standard Deviation 0.220	0.82 log10 IU/mL Standard Deviation 0.216

SECONDARY outcome

Timeframe: IP: Baseline, Weeks 2, 4, 8, 12, 16, 20, and EOSI (Week 24); FU Phase: FU Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, and EOS (last visit at FU Week 48)

Percentage of participants with HBV DNA level below/above different cut-offs over time were reported. HBV DNA cut offs: \<LLOQ target detected (TD): that is, traces of HBV DNA were detected/found but were too low to be quantified; \<LLOQ target not detected (TND): that is, no traces of HBV DNA were detected/found. EOSI was the last post-baseline visit in study intervention period. EOS was the last visit in the study. The LLOQ for HBV DNA was 20 IU/mL. As indicated in the data table, the sum of percentage values of each sub-categories within the specific timepoints "IP: Week 2" and "FU Phase: Week 4", shows a slight deviation from 100% due to rounding.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 2: HBV DNA < LLOQ TD	27.8 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 2: HBV DNA > LLOQ	5.6 Percentage of participants	0 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Baseline: HBV DNA < LLOQ TND	72.2 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Baseline: HBV DNA < LLOQ TD	27.8 Percentage of participants	21.1 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 2: HBV DNA < LLOQ TND	66.7 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 4: HBV DNA < LLOQ TND	72.2 Percentage of participants	68.4 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 4: HBV DNA < LLOQ TD	27.8 Percentage of participants	31.6 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 8: HBV DNA < LLOQ TND	61.1 Percentage of participants	73.7 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 8: HBV DNA < LLOQ TD	38.9 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 12: HBV DNA < LLOQ TND	61.1 Percentage of participants	73.7 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 12: HBV DNA < LLOQ TD	38.9 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 16: HBV DNA <LLOQ TND	55.6 Percentage of participants	73.7 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 16: HBV DNA <LLOQ TD	44.4 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 20: HBV DNA <LLOQ TND	66.7 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: Week 20: HBV DNA <LLOQ TD	33.3 Percentage of participants	21.1 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: EOSI(Week 24): HBV DNA <LLOQ TND	50.0 Percentage of participants	84.2 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: EOSI(Week 24): HBV DNA <LLOQ TD	38.9 Percentage of participants	15.8 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time IP: EOSI(Week 24): HBV DNA > LLOQ	11.1 Percentage of participants	0 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBV DNA <LLOQ TND	72.2 Percentage of participants	63.2 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBV DNA <LLOQ TD	27.8 Percentage of participants	31.6 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 4: HBV DNA > LLOQ	0 Percentage of participants	5.3 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBV DNA <LLOQ TND	72.2 Percentage of participants	78.9 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 8: HBV DNA <LLOQ TD	27.8 Percentage of participants	21.1 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBV DNA <LLOQ TND	52.9 Percentage of participants	55.6 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBV DNA <LLOQ TD	41.2 Percentage of participants	44.4 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 12: HBV DNA > LLOQ	5.9 Percentage of participants	0 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBV DNA <LLOQ TND	83.3 Percentage of participants	68.4 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 16: HBV DNA <LLOQ TD	16.7 Percentage of participants	31.6 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBV DNA <LLOQ TND	66.7 Percentage of participants	58.8 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 20: HBV DNA <LLOQ TD	33.3 Percentage of participants	41.2 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBV DNA <LLOQ TND	66.7 Percentage of participants	63.2 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 24: HBV DNA <LLOQ TD	33.3 Percentage of participants	36.8 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBV DNA <LLOQ TND	61.1 Percentage of participants	89.5 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 32: HBV DNA <LLOQ TD	38.9 Percentage of participants	10.5 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBV DNA <LLOQ TND	55.6 Percentage of participants	68.4 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 40: HBV DNA <LLOQ TD	44.4 Percentage of participants	31.6 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBV DNA <LLOQ TND	70.6 Percentage of participants	73.7 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: Week 48: HBV DNA <LLOQ TD	29.4 Percentage of participants	26.3 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: EOS: HBV DNA <LLOQ TND	72.2 Percentage of participants	73.7 Percentage of participants
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Level Below/Above Different Cut-offs Over Time FU Phase: EOS: HBV DNA <LLOQ TD	27.8 Percentage of participants	26.3 Percentage of participants

SECONDARY outcome

Timeframe: IP: Baseline, Weeks 2, 4, 8, 12, 20, and EOSI (Week 24); FU Phase: FU Weeks 12, 16, 20, 24, 32, 40, 48, and EOS (last visit at FU Week 48)

Percentage of participants with HBeAg level below/above different cut-offs over time were reported. HBeAg cut-offs: \<LLOQ (0.11 IU/mL). EOSI was the last post-baseline visit in study intervention period. EOS was the last visit in the study.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: Baseline	100.0 Percentage of participants	94.7 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: Week 2	—	100 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: Week 4	—	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: Week 8	—	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: Week 12	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: Week 20	—	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time IP: EOSI (Week 24)	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: Week 12	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: Week 16	—	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: Week 24	100.0 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: Week 32	—	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: Week 40	100.0 Percentage of participants	—
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: Week 48	94.1 Percentage of participants	100.0 Percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Level Below/Above Different Cut-offs Over Time FU Phase: EOS	94.4 Percentage of participants	100.0 Percentage of participants

SECONDARY outcome

Timeframe: IP: Week 0 to Week 24; FU Phase: FU Week 1 up to FU Week 48

Population: FAS included all participants who were randomly assigned to an intervention arm in this intervention-specific appendix (ISA) and received at least 1 dose of study intervention within this ISA.

Percentage of participants with virologic breakthrough (confirmed on-treatment HBV DNA increase by \>1 log10 IU/mL from nadir in participants who did not have on-treatment HBV DNA level below LLOQ or a confirmed on-treatment HBV DNA level \>200 IU/mL in participants who had on-treatment HBV DNA level below LLOQ) were reported.

Outcome measures

Outcome measures
Measure	JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA n=18 Participants In intervention phase (IP), participants received a loading dose of JNJ-3989 200 milligrams (mg) as subcutaneous (SC) injection once weekly (QW) for first 4 weeks starting from Week 0 up to Week 3 followed by single dose once every 4 weeks (Q4W) from Week 4 up to Week 24. At Week 16, participants received a single dose of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or tenofovir alafenamide \[TAF\] 25 mg or entecavir \[ETV\] 0.5 mg) tablet orally once daily (QD) from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).	JNJ-3989 + Nivolumab (3 Infusions) + NA n=19 Participants In IP, participants received a loading dose of JNJ-3989 200 mg as SC injection QW for first 4 weeks starting from Week 0 up to Week 3 followed by single dose Q4W from Week 4 up to Week 24. At Weeks 16, 20 and 24, participants received of nivolumab 0.3 mg/kg as IV infusion. Participants also received NA (either tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD from Week 0 up to Week 24. After Week 24, participants were followed up for safety for 48 weeks during which they continued to receive NA (tenofovir disoproxil 245 mg or TAF 25 mg or ETV 0.5 mg) tablet orally QD up to FU Week 48 (up to Week 72).
Percentage of Participants With Virologic Breakthrough IP	0 Percentage of participants	0 Percentage of participants
Percentage of Participants With Virologic Breakthrough FU Phase	0 Percentage of participants	0 Percentage of participants

Adverse Events

IP: JNJ-73763989 (JNJ-3989) + Nivolumab (1 Infusion) + NA

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

IP: JNJ-3989 + Nivolumab (3 Infusions) + NA

Serious events: 0 serious events

Other events: 12 other events

Deaths: 0 deaths

FU: JNJ-3989 + Nivolumab (1 Infusion) + NA

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

FU: JNJ-3989 + Nivolumab (3 Infusions) + NA

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Additional Information

Executive Medical Director

Janssen Research & Development, LLC

Phone: 844-434-4210

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.
Publication restrictions are in place

Restriction type: OTHER